<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36952594</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>The third dose of BNT162b2 COVID-19 vaccine is efficacious and safe for systemic lupus erythematosus patients receiving belimumab.</ArticleTitle><Pagination><StartPage>675</StartPage><EndPage>679</EndPage><MedlinePgn>675-679</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09612033231164262</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Over 95% of healthy subjects develop anti-COVID IgG antibodies after receiving two doses of BNT162b2 COVID-19 vaccine. In comparison, 20%-30% of SLE patients do not seroconvert following 1-2 doses of COVID vaccines, potentially due to immunosuppression. The aim of this study was to assess immunogenicity and safety of BNT vaccine in SLE patients treated with Belimumab and especially the yield of a booster third dose in this population.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">SLE patients treated with Belimumab in the Sheba Medical Center, Israel, were included in this study. All were recommended to receive the BNT vaccine according to national guidelines; and were advised to perform serologic tests after receiving second and third doses. Clinical data included demographics, SLE treatments, adverse effects to vaccines and SLEDAI scores performed 2&#xa0;weeks before vaccinations and 6-12&#xa0;weeks after receiving the second or third dose of the vaccine.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our cohort included 17 patients, 14 (82.35%) females, median age 50 &#xb1; 14.2&#xa0;years, and disease duration 12 &#xb1; 10.57&#xa0;years. Belimumab therapy was given for a mean of 6 &#xb1; 2.5&#xa0;years. Of them, 15/17 patients received 3-doses of BNT vaccine. Serologic assessment was performed for 10 patients, 7/10(70%) became seropositive following the second dose, while 2/3 patients seroconverted only after the third dose. Vaccinations were well tolerated with minimal adverse events and no disease flares. SLEDAI scores before and after vaccinations were 4 &#xb1; 3.8 and 4 &#xb1; 2.7 (<i>p</i> = 0.69), respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Immunization with the BNT vaccine is efficacious and safe for SLE patients treated with Belimumab. Following the third dose of vaccine, immunogenicity among SLE patients mounted to 90%, thereby approximating the general healthy population. No SLE disease flares and/or significant adverse events were noted in our cohort. Assessment of seroconversion and consideration of subsequent boosters of COVID-vaccine should be considered in this group of patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tunitsky-Lifshitz</LastName><ForeName>Yulia</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0380-6283</Identifier><AffiliationInfo><Affiliation>Clinical Immunology, Angioedema and Allergy Unit, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel.</Affiliation><Identifier Source="RINGGOLD">26744</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Sackler School of Medicine, Tel Aviv University, Ramat-Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maoz-Segal</LastName><ForeName>Ramit</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Immunology, Angioedema and Allergy Unit, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel.</Affiliation><Identifier Source="RINGGOLD">26744</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niznik</LastName><ForeName>Stanley</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Immunology, Angioedema and Allergy Unit, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel.</Affiliation><Identifier Source="RINGGOLD">26744</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shavit</LastName><ForeName>Ronen</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Immunology, Angioedema and Allergy Unit, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel.</Affiliation><Identifier Source="RINGGOLD">26744</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haj Yahia</LastName><ForeName>Soad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Immunology, Angioedema and Allergy Unit, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel.</Affiliation><Identifier Source="RINGGOLD">26744</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Sackler School of Medicine, Tel Aviv University, Ramat-Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langevitz</LastName><ForeName>Pnina</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Sackler School of Medicine, Tel Aviv University, Ramat-Aviv, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology Unit, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel.</Affiliation><Identifier Source="RINGGOLD">26744</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agmon-Levin</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Immunology, Angioedema and Allergy Unit, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel.</Affiliation><Identifier Source="RINGGOLD">26744</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Sackler School of Medicine, Tel Aviv University, Ramat-Aviv, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>73B0K5S26A</RegistryNumber><NameOfSubstance UI="C511911">belimumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090982">BNT162 Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090982" MajorTopicYN="N">BNT162 Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BNT 162b2 vaccine</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">booster</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>23</Day><Hour>15</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36952594</ArticleId><ArticleId IdType="pmc">PMC10037128</ArticleId><ArticleId IdType="doi">10.1177/09612033231164262</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lustig Y, Sapir E, Regev-Yochay G, et al.BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir Med 2021; 9: 999&#x2013;1009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8253545</ArticleId><ArticleId IdType="pubmed">34224675</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn BH. Belimumab for systemic lupus erythematosus. N Engl J Med 2013; 368(16): 1528&#x2013;1535. DOI: 10.1056/nejmct1207259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmct1207259</ArticleId><ArticleId IdType="pubmed">23594005</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Rovin BH, Houssiau F, et al.Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 2020; 383(12): 1117&#x2013;1128. DOI: 10.1056/nejmoa2001180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2001180</ArticleId><ArticleId IdType="pubmed">32937045</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy RA, Gonzalez-Rivera T, Khamashta M, et al.10&#xa0;years of belimumab experience: what have we learnt? Lupus 2021; 30(11): 1705&#x2013;1721. DOI: 10.1177/09612033211028653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211028653</ArticleId><ArticleId IdType="pmc">PMC8564244</ArticleId><ArticleId IdType="pubmed">34238087</ArticleId></ArticleIdList></Reference><Reference><Citation>Sthoeger Z, Lorber M, Tal Y, et al.Anti-BlyS treatment of 36 Israeli systemic lupus erythematosus patients. Isr Med Assoc J 2017; 19: 44&#x2013;48, https://www.ima.org.il/FilesUploadPublic/IMAJ/0/224/112284.pdf</Citation><ArticleIdList><ArticleId IdType="pubmed">28457114</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;rner T, Lipsky PE. Beyond pan-B-cell-directed therapy &#x2014; new avenues and insights into the pathogenesis of SLE. Nat Rev Rheumatol 2016; 12(11): 645&#x2013;657. DOI: 10.1038/nrrheum.2016.158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2016.158</ArticleId><ArticleId IdType="pubmed">27733759</ArticleId></ArticleIdList></Reference><Reference><Citation>Furer V, Rondaan C, Heijstek MW, et al.2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020; 79(1): 39&#x2013;52. DOI: 10.1136/annrheumdis-2019-215882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215882</ArticleId><ArticleId IdType="pubmed">31413005</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkayam O, Paran D, Caspi D, et al.Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002; 34(2): 147&#x2013;153. DOI: 10.1086/338043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/338043</ArticleId><ArticleId IdType="pubmed">11740700</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdaca G, Orsi A, Span&#xf2; F, et al.Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: current views upon safety and immunogenicity. Autoimmun Rev 2014; 13(2): 75&#x2013;84. DOI: 10.1016/j.autrev.2013.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2013.07.007</ArticleId><ArticleId IdType="pubmed">24044940</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadun RE, Eudy AM, Rogers JL, et al.1205 COVID-19 vaccine beliefs amongst individuals living with lupus. Lupus Science and Medicine 2021; 8(Suppl 2): A53. DOI: 10.1136/lupus-2021-lupus21century.72.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-lupus21century.72</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, et al.2019 European league against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019; 71(9): 1400&#x2013;1412. DOI: 10.1002/art.40930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40930</ArticleId><ArticleId IdType="pmc">PMC6827566</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId></ArticleIdList></Reference><Reference><Citation>Moyon Q, Sterlin D, Miyara M, et al.BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. Ann Rheum Dis 2021; 81(4): 575&#x2013;583. DOI: 10.1136/annrheumdis-2021-221097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221097</ArticleId><ArticleId IdType="pmc">PMC8494536</ArticleId><ArticleId IdType="pubmed">34607791</ArticleId></ArticleIdList></Reference><Reference><Citation>Izmirly PM, Kim MY, Samanovic M, et al.Evaluation of immune response and disease status in systemic lupus erythematosus patients following SARS-CoV-2 vaccination. Arthritis Rheumatol 2022; 74: 284&#x2013;294. DOI: 10.1002/art.41937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41937</ArticleId><ArticleId IdType="pmc">PMC8426963</ArticleId><ArticleId IdType="pubmed">34347939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ammitzb&#xf8;ll C, Bartels LE, B&#xf8;gh Andersen J, et al.Impaired antibody response to the BNT162b2 messenger RNA coronavirus disease 2019 vaccine in patients with systemic lupus erythematosus and rheumatoid arthritis. ACR Open Rheumatol 2021; 3(9): 622&#x2013;628. DOI: 10.1002/acr2.11299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11299</ArticleId><ArticleId IdType="pmc">PMC8426741</ArticleId><ArticleId IdType="pubmed">34273260</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatham WW, Wallace DJ, Stohl W, et al. BLISS-76 Study Group , Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. J Rheumatol 2012; 39(8): 1632&#x2013;1640. DOI: 10.3899/jrheum.111587.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.111587</ArticleId><ArticleId IdType="pubmed">22707609</ArticleId></ArticleIdList></Reference><Reference><Citation>Adawi M, Bragazzi NL, McGonagle D, et al.Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: an evidence-informed and PRISMA compliant systematic review and meta-analysis. Autoimmun Rev 2019; 18(1): 73&#x2013;92. DOI: 10.1016/j.autrev.2018.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2018.08.002</ArticleId><ArticleId IdType="pubmed">30408581</ArticleId></ArticleIdList></Reference><Reference><Citation>Furer V, Eviatar T, Zisman D, et al.Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 2021; 80(10): 1330&#x2013;1338. DOI: 10.1136/annrheumdis-2021-220647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220647</ArticleId><ArticleId IdType="pubmed">34127481</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang W, Gartshteyn Y, Ricker E, et al.The use of COVID-19 vaccines in patients with SLE. Curr Rheumatol Rep 2021; 23(11): 79. DOI: 10.1007/s11926-021-01046-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-021-01046-2</ArticleId><ArticleId IdType="pmc">PMC8586600</ArticleId><ArticleId IdType="pubmed">34767100</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels LE, Ammitzb&#xf8;ll C, Andersen JB, et al.Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int 2021; 41(11): 1925&#x2013;1931. DOI: 10.1007/s00296-021-04972-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-021-04972-7</ArticleId><ArticleId IdType="pmc">PMC8412379</ArticleId><ArticleId IdType="pubmed">34476603</ArticleId></ArticleIdList></Reference><Reference><Citation>Zavala-Flores E, Salcedo-Matienzo J, Quiroz-Alva A, et al.Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus. Clin Rheumatol 2022; 41(5): 1349&#x2013;1357. DOI: 10.1007/s10067-021-05980-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-021-05980-5</ArticleId><ArticleId IdType="pmc">PMC8592807</ArticleId><ArticleId IdType="pubmed">34782941</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>